Wells Fargo downgraded Zymeworks (ZYME) to Equal Weight from Overweight with an unchanged price target of $12. The firm believes the shares are “fully valued” following the company’s Q3 report. Wells cites valuation for the downgrade.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter